University of Sheffield spinout company, Rinri Therapeutics, a company focused on developing new treatments for hearing loss ...

Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

These CENP-A proteins ensure that divided genetic information is kept intact during mitosis.

Gene mutations have consequences both good and bad—from resistance to conditions like diabetes to susceptibility to certain ...